A Phase 1 Dose Escalation and Pharmacodynamic Study of ARQ 761 (Beta-Lapachone) in Adult Patients With Advanced Solid Tumors
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 91
- 试验地点
- 1
- 主要终点
- Maximum Tolerated Dose (MTD)
研究概览
简要总结
Primary Objective:
To determine the safety, tolerability and recommended Phase 2 dose (RP2D) of ARQ 761 administered intravenously.
Secondary Objectives:
To determine the pharmacokinetic profile of ARQ 761 To assess the preliminary anti-tumor activity of aRQ 761
详细描述
This is an open label, dose escalation study of (-)-trans-3-(5,6-dihydro-4H-pyrrolo [3,2,1-ij] quinolin-1-yl)-4(1Hindol-3-yl) pyrrolidine-2,5-dione (ARQ) 761. Drug administration regimen was designed in two parts.
Part I is a single-arm, non-randomized dose-escalation study. Part II is a multi-arm, randomized dose-escalation study. It is designed to establish the clinical tolerability and MTD of ARQ 761 and a recommended Phase 2 dose (RP2D). This is the first-in-human study with ARQ 761.
Part I ARQ 761 will be administered intravenously at a starting dose of 195 mg/m2 IV once weekly. A cycle for any patient already enrolled will consist of weekly administration of ARQ 761 with cycles repeated every 4 weeks (28 days).
Part II Alternate dosing regimen of ARQ 761 will be evaluated at a starting dose of 390 mg/m2. ARQ 761 will be administered intravenously at the assigned duration (2 h or 3 h) weekly, biweekly or for two consecutive weeks followed by one week of rest. Patient will be randomized to Arm A, B or C after enrollment.
Depending on toxicities observed, up to seven treatment cohorts will be enrolled with dose escalation occurring by doubling (first escalation) and 40% increments thereafter. If dosing is tolerated at all levels and pharmacokinetic data suggest continued escalation is warranted, additional dose levels will be considered. Patients enrolled and assessed for dose limiting toxicities (DLTs) will be eligible for intra-patient dose escalation.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subjects must have a confirmed solid tumor that is metastatic, unresectable or recurrent and for which standard curative or palliative measures do not exist or are no longer effective.
- •Prior and concurrent therapy:
- •Chemotherapy: At least four weeks since prior cytotoxic chemotherapy or 6 weeks since nitrosoureas or mitomycin.
- •Molecular targeted agents including monoclonal antibodies and tyrosine kinase inhibitors: At least two weeks since last therapy.
- •Endocrine therapy: Subject may be remain on LHRH antagonist therapy for prostate cancer if tumor progression has been confirmed.
- •Radiotherapy: At least 3 weeks since most recent radiotherapy. Other investigational therapy: At least four weeks since any other investigational therapy.
- •Concurrent therapy: No other concurrent anticancer or investigational therapy permitted except as noted above.
- •Measurable disease is not required, but will be evaluated in each subject when possible.
- •Age ≥18 years
- •Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1
- •Life expectancy ≥ three months.
- •Central venous access, such as a Portacath or Hickman Line.
- •Pretreatment clinical laboratory parameters within 14 days
- •Availability of 10 unstained slides or paraffin-embedded tissue block from archived tumor specimen.
- •Subjects must be recovered from any toxicity related to prior anti-neoplastic therapy (to grade <1). Patients with CTCAE grade 2 or less sensory neuropathy or any grade alopecia are eligible.
排除标准
- •Subjects who have had cytotoxic chemotherapy or treatment with monoclonal antibodies within 4 weeks, radiotherapy within 3 weeks, or other molecular targeted therapies.
- •Subjects may not be receiving any other investigational agents.
- •Subjects with known untreated brain metastases. Subjects with known, treated brain metastases must be stable with no symptoms for four weeks.
- •Subjects receiving enzyme-inducing antiseizure drugs ("EIASD").
- •Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, significant pulmonary disease (shortness of breath at rest or mild exertion), uncontrolled infection or psychiatric illness/social situations that would limit compliance with study requirements.
- •Pregnant women and breastfeeding should be discontinued.
- •Absence of central venous access for administration of the study drug.
研究组 & 干预措施
Part 1 (ARQ 761)
ARQ 761 (beta lapachone) will be given once a week. The same dose of ARQ761 each week for 4 weeks (1 cycle = 28 days). The total infusion time will be one (1) hour.
Beginning dose level will be 195 mg/m2 and will increase until the maximum tolerated dose is defined. Seven dose levels that may be administered:
1-195 mg/m2 2-390 mg/m2 3-450 mg/m2 4-550 mg/m2 5-660 mg/m2 6-800 mg/m2 7-1000 mg/m2
干预措施: ARQ 761 (Drug)
Part 2 Arm A
The same dose of ARQ761 will be given each week for 8 weeks. The total infusion time will be 2 or 3 hours.
Beginning dose level will be 390 mg/m2.
干预措施: ARQ 761 Weekly Administration (Drug)
Part 2 Arm B
ARQ 761 (beta lapachone) will be given bi-weekly for 8 weeks. The total infusion time may be either 2 or 3 hours.
The beginning dose level will be 390 mg/m2.
干预措施: Bi-Weekly Administration of ARQ 761 (Drug)
Part 2 Arm C
ARQ 761 (beta lapachone) will be given 2 consecutive weeks followed by one week of rest for 6 weeks. The total infusion time will be 2 or 3 hours.
The beginning dose level will be 390 mg/m2.
干预措施: Two Consecutive Weeks Administration of ARQ 761 with one week of rest (Drug)
结局指标
主要结局
Maximum Tolerated Dose (MTD)
时间窗: Patients will receive an average of 4 cycles of ARQ 761 (corresponding with a treatment cycle of 16 weeks).
To determine the recommended Phase 2 dose (RP2D) of ARQ 761 administered intravenously.
次要结局
- Pharmacokinetic profile of ARQ761(Samples will be drawn from each subject during first and fourth infusion of study drug)